(Q34443530)

2 August 2017

1 reference

title

Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? (English)

1 reference

2 August 2017

main subject

botulinum toxin type A

1 reference

Jürgen Frevert

1

1 reference

2 August 2017

Dirk Dressler

series ordinal

2

1 reference

2 August 2017

publication date

9 December 2010

1 reference

Biologics: Targets and Therapy

2 August 2017

published in

1 reference

2 August 2017

volume

4

1 reference

2 August 2017

page(s)

325-332

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

2 August 2017

copyright license

start time

1 December 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Evidence for effectiveness of botulinum toxin for hyperhidrosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Using translational medicine to understand clinical differences between botulinum toxin formulations

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Molecular composition of Clostridium botulinum type A progenitor toxins

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Molecular genetics of clostridial neurotoxins

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Organization of the botulinum neurotoxin C1 gene and its associated non-toxic protein genes in Clostridium botulinum C 468.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Oral toxicities of Clostridium botulinum toxins in response to molecular size

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Botulinum toxin in the treatment of OAB, BPH, and IC.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

[Pharmacological aspects of therapeutic botulinum toxin preparations].

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3010823

On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin

27 October 2018

1 reference

12 December 2020

Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications

1 reference

12 December 2020

Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers

1 reference

12 December 2020

A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function

1 reference

12 December 2020

Routine use of Xeomin in patients previously treated with Botox: long term results

1 reference

12 December 2020

Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group

1 reference

12 December 2020

Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure

1 reference

12 December 2020

Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences

1 reference

12 December 2020

Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg

1 reference

12 December 2020

Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm

1 reference

12 December 2020

Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins

1 reference

12 December 2020

A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity

1 reference

12 December 2020

Immunological properties of Hn-33 purified from type A Clostridium botulinum

1 reference

12 December 2020

Identifiers

DOI

10.2147/BTT.S14902

1 reference

2 August 2017

1 reference

2 August 2017

1 reference